The Hepatoprotection Provided by Taurine and Glycine against Antineoplastic Drugs Induced Liver Injury in an Ex Vivo Model of Normothermic Recirculating Isolated Perfused Rat Liver

Document Type : Research(Original) Article


1 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Pharmacology and Toxicology Department, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

3 Department of Pharmacology-Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

4 Pharmacology and Toxicology Department, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

5 Food and Drug Organization, Ministry of Health, Tehran, Iran.

6 Center of Experimental & Comparative Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Department of Animal Science, School of Agriculture, Shiraz University, Shiraz, Iran


Taurine (2-aminoethane sulfonic acid) is a non-protein amino acid found in high concentration in different tissues. Glycine (Amino acetic acid) is the simplest amino acid incorporated in the structure of proteins. Several investigations indicate the hepatoprotective properties of these amino acids. On the other hand, antineoplastic agents-induced serum transaminase elevation and liver injury is a clinical complication. The current investigation was designed to screen the possible hepatoprotective properties of taurine and glycine against antineoplastic drugs-induced hepatic injury in an ex vivo model of isolated perfused rat liver. Rat liver was perfused with different concentration (10 µM, 100 µM and 1000 µM) of antineoplastic drugs (Mitoxantrone, Cyclophosphamide, Cisplatin, 5‑Fluorouracil, Doxorubicin and Dacarbazine) via portal vein. Taurine and glycine were administered to drug-treated livers and liver perfusate samples were collected for biochemical measurements (ALT, LDH, AST, and K+). Markers of oxidative stress (reactive oxygen species formation, lipid peroxidation, total antioxidant capacity and glutathione) were also assessed in liver tissue. Antineoplastic drugs caused significant pathological changes in perfusate biochemistry. Furthermore, markers of oxidative stress were significantly elevated in drug‑treated livers. It was found that taurine (5 and 10 mM) and glycine (5 and 10 mM) administration significantly mitigated the biomarkers of liver injury and attenuated drug‑induced oxidative stress. Our data indicate that taurine and glycine supplementation might help as potential therapeutic options to encounter anticancer drugs-induced liver injury.


  1. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: Mechanisms and test systems. Hepatology 2001;33;1009-1013.
  2. El-Sayyad HI, Ismail MF, Shalaby FM, Abou-El-Magd RF, Gaur RL, Fernando A, Raj MHG, Ouhtit A. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. International Journal of Biological Sciences 2009;5;466-473.
  3. Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. Journal of hepato-biliary-pancreatic surgery 2009;16;137-144.
  4. Thatishetty AV, Agresti N, O'Brien CB. Chemotherapy-induced hepatotoxicity. Clinics in liver disease 2013;17;671-686.
  5. Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, DeLeve LD, others, Liver Function and Hepatotoxicity in Cancer; 2000, New York.
  6. Erman F, Tuzcu M, Orhan C, Sahin N, Sahin K. Effect of lycopene against cisplatin-induced acute renal injury in rats: organic anion and cation transporters evaluation. Biol Trace Element Res 2014;158;90-95.
  7. Nematbakhsh M, Ashrafi F, Pezeshki Z, Fatahi Z, Kianpoor F, Sanei M-H, Talebi A. A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: Which one is the first observation as side effect of Cisplatin-induced toxicity in animal model? J Nephropathol 2012;1;190-193.
  8. Henninger C, Huelsenbeck S, Wenzel P, Brand M, Huelsenbeck J, Schad A, Fritz G. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. Pharmacol Res 2015;91;47-56.
  9. King PD, Perry MC. Hepatotoxicity of Chemotherapy. The Oncologist 2001;6;162-176.
  10. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, DeLeve LD, others, Hepatotoxicity by Anticancer Therapy; 2003.
  11. Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Europ J Surg Oncol 2008;34;1231-1236.
  12. Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the liver after chemotherapy of acute leukemia: report of two cases. Annals Internal Med 1976;85;578-582.
  13. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, others. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Annals of Oncology 2004;15;460-466.
  14. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. British Journal of Surgery 2007;94;274-286.
  15. De Jonge ME, Huitema ADR, Beijnen JH, Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Brit J Cancer 2006;94;1226-1230.
  16. Frosch PJ, Czarnetzki BM, Macher E, Grundmann E, Gottschalk I. Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma. J Cancer Res Clin Oncol 1979;95;281-286.
  17. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101;2043-2048.
  18. Lourenco R, Camilo ME, others. Taurine: a conditionally essential amino acid in humans? An overview in health and disease. Nutr Hosp 2002;17;262-270.
  19. Huxtable RJ, others. Physiological actions of taurine. Physiol rev 1992;72;101-63.
  20. Pasantes-Morales H, Quesada O, Moran J, Taurine: an osmolyte in mammalian tissues, in Taurine 31998, Springer. p. 209-217.
  21. Atmaca G. Antioxidant effects of sulfur-containing amino acids. Yonsei Med J 2004;45;776-788.
  22. Oja SS, Saransaari P. Pharmacology of taurine. Proc West Pharmacol Soc 2007;50;8-15.
  23. Islambulchilar M, Asvadi I, Sanaat Z, Esfahani A, Sattari M. Taurine attenuates chemotherapy-induced nausea and vomiting in acute lymphoblastic leukemia. Amino acids 2015;47;101-109.
  24. Motawi TK, Abd Elgawad HM, Shahin NN. Modulation of indomethacin-induced gastric injury by spermine and taurine in rats. J Biochem Mol Toxicol 2007;21;280-288.
  25. Oja SS, Saransaari P. Taurine and epilepsy. Epilepsy Res 2013;104;187-194.
  26. Marcinkiewicz J, Kontny E. Taurine and inflammatory diseases. Amino Acids 2014;46;7-20.
  27. Timbrell JA, Seabra V, Waterfield CJ. The in vivo and in vitro protective properties of taurine. Gen Pharmacol Vasc System 1995;26;453-462.
  28. Das J, Roy A, Sil PC. Mechanism of the protective action of taurine in toxin and drug induced organ pathophysiology and diabetic complications: a review. Food Function 2012;3;1251-1264.
  29. Das J, Ghosh J, Manna P, Sil PC. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: Protective role of taurine by the suppression of cytochrome P450 2E1. Free Rad Res 2010;44;340-355.
  30. Heidari R, Babaei H, Eghbal MA. Amodiaquine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine. Res Pharm Sci 2014;9.
  31. Heidari R, Babaei H, Eghbal MA. Ameliorative Effects of Taurine Against Methimazole-Induced Cytotoxicity in Isolated Rat Hepatocytes. Sci Pharm 2012;80;987-999.
  32. Bo-gelmez p, Soylemezoolu T, Guvendik G. The Protective and Antidotal Effects of Taurine on Hexavalent Chromium-Induced Oxidative Stress in Mice Liver Tissue. Biolog Trace Element Res 2008;125;46-58.
  33. Das J, Ghosh J, Manna P, Sil PC. Taurine protects acetaminophen-induced oxidative damage in mice kidney through APAP urinary excretion and CYP2E1 inactivation. Toxicology 2010;269;24-34.
  34. Dinçer S, Özenirler S, Öz E, Akyol G, Özoğul C. The protective effect of taurine pretreatment on carbon tetrachloride-induced hepatic damage – A light and electron microscopic study. Amino Acids 2002;22;417-426.
  35. Doğru-Abbasoğlu S, Kanbağli O, Balkan J, Cevikbaş U, Aykaç-Toker G, Uysal M. The protective effect of taurine against thioacetamide hepatotoxicity of rats. Hum Exp Toxicol 2001;20;23-27.
  36. Ghosh M, Pal S, Sil PC. Taurine attenuates nano-copper-induced oxidative hepatic damage via mitochondria-dependent and NF-κB/TNF-α-mediated pathway. Toxicol Res 2014;3;474-486.
  37. Hagar HH. The protective effect of taurine against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Toxicol Lett 2004;151;335-343.
  38. Heidari R, Babaei H, Eghbal MA. Cytoprotective effects of taurine against toxicity induced by isoniazid and hydrazine in isolated rat hepatocytes. Arch Ind Hyg Toxicol 2013;64;201-210.
  39. Jagadeesan G, Pillai SS. Hepatoprotective effects of taurine against mercury induced toxicity in rat. J Envir Biol 2007;28;753.
  40. Kerai MD, Waterfield CJ, Kenyon SH, Asker DS, Timbrell JA. Taurine: protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats. Amino Acids 1998;15;53-76.
  41. Koyama I, Nakamura T, Ogasawara M, Nemoto M, Yoshida T, The protective effect of taurine on the biomembrane against damage produced by the oxygen radical, in Taurine1992, Springer. p. 355-359.
  42. You JS, Chang KJ. Taurine protects the liver against lipid peroxidation and membrane disintegration during rat hepatocarcinogenesis. Adv Exp Med Biol 1998;442;105-112.
  43. Shao A, Hathcock JN. Risk assessment for the amino acids taurine, l-glutamine and l-arginine. Regulat Toxicol Pharmacol 2008;50;376-399.
  44. Kibayashi E, Yokogoshi H, Mizue H, Miura K, Yoshita K, Nakagawa H, Naruse Y, Sokejima S, Kagamimori S. Daily dietary taurine intake in Japan. Adv Exp Med Biol 2000;483;137-142.
  45. Zhao X, Jia J, Lin Y. Taurine content in Chinese food and daily intake of Chinese men. Advances in experimental medicine and biology 1998;442;501.
  46. Bruns H, Watanpour I, Gebhard M, Flechtenmacher C, Galli U, Schulze-Bergkamen H, Zorn M, Buechler MW, Schemmer P. Glycine and Taurine Equally Prevent Fatty Livers from Kupffer Cell-Dependent Injury: An In Vivo Microscopy Study. Microcirculation 2011;18;205-213.
  47. Pal PB, Pal S, Das J, Sil PC. Modulation of mercury-induced mitochondria-dependent apoptosis by glycine in hepatocytes. Amino Acids 2011;42;1669-1683.
  48. Chen C-Y, Wang B-T, Wu Z-C, Yu W-T, Lin P-J, Tsai W-L, Shiesh S-C. Glycine ameliorates liver injury and vitamin D deficiency induced by bile duct ligation. Clinica Chimica Acta 2013;420;150-154.
  49. Weinberg JM, Roeser NF, Davis JA, Venkatachalam MA. Kidney International - Abstract of article: Glycine-protected, hypoxic, proximal tubules develop severely compromised energetic function. Kidney Int 1997;52;140-151.
  50. Wheeler MD, Rose ML, Yamashima S, Enomoto N, Seabra V, Madren J, Thurman RG. Dietary glycine blunts lung inflammatory cell influx following acute endotoxin. Amr J Physiol 2000;279;L390-L398.
  51. Warnecke G, Schulze B, Steinkamp T, Haverich A, Klima U. Glycine application and right heart function in a porcine heart transplantation model. Transplant Int 2006;19;218-224.
  52. Sommer S-P, Sommer S, Sinha B, Leyh RG. Glycine preconditioning to ameliorate pulmonary ischemia reperfusion injury in rats. Interact Cardiovasc Thoracic Surg 2012;14;521-525.
  53. Carini R, Alchera E, Baldanzi G, Piranda D, Splendore R, De Cesaris MG, Caraceni P, Graziani A, Albano E. Role of p38 map kinase in glycine-induced hepatocyte resistance to hypoxic injury. J Hepatol 2007;46;692-699.
  54. Shaikh ZA, Tang W. Protection against chronic cadmium toxicity by glycine. Toxicology 1999;132;139-146.
  55. Ingawale DK, Mandlik SK, Naik SR. Models of hepatotoxicity and the underlying cellular, biochemical and immunological mechanism(s): A critical discussion. Envir Toxicol Pharmacol 2014;37;118-133.
  56. Wolkoff AW, Johansen KL, Goeser T. The isolated perfused rat liver: preparation and application. Analyt Bochem 1987;167;1-14.
  57. Ferrigno A, Richelmi P, Vairetti M. Troubleshooting and improving the mouse and rat isolated perfused liver preparation. J Pharmacol Toxicol Methods 2012;67;107-114.
  58. Bessems M, Tolba R, Doorschodt BM, Leuvenink HGD, Ploeg RJ, Minor T, van Gulik TM, others. The isolated perfused rat liver: standardization of a time-honoured model. Laboratory animals 2006;40;236-246.
  59. Gupta R, Dubey DK, Kannan GM, Flora SJS. Concomitant administration of Moringa oleifera seed powder in the remediation of arsenic-induced oxidative stress in mouse. Cell Biol Int 2007;31;44-56.
  60. Socci DJ, Bjugstad KB, Jones HC, Pattisapu JV, Arendash GW. Evidence that oxidative stress is associated with the pathophysiology of inherited hydrocephalus in the H-Tx rat model. Exp Neurol 1999;155;109-17.
  61. Heidari R, Taheri V, Rahimi HR, Yeganeh BS, Niknahad H, Najibi A. Sulfasalazine-induced renal injury in rats and the protective role of thiol-reductants. Renal Failure 2015;In Press;1-5.
  62. Sedlak J, Lindsay R. Estimation of Total, Protein-Bound, and Nonprotein Sulfhydryl Groups in Tissue with Ellman’s Reagent Analyt Biochem 1968;25;192-205.
  63. Heidari R, Babaei H, Roshangar L, Eghbal MA. Effects of Enzyme Induction and/or Glutathione Depletion on Methimazole-Induced Hepatotoxicity in Mice and the Protective Role of N-Acetylcysteine. Adv Pharm Bull 2014;4;21-28.
  64. Heidari R, Jamshidzadeh A, Keshavarz N, Azarpira N. Mitigation of Methimazole-Induced Hepatic Injury by Taurine in Mice. Sci Pharm 2015;83;143-158.
  65. Heidari R, Taheri V, Rahimi HR, Shirazi Yeganeh B, Niknahad H, Najibi A. Sulfasalazine-induced renal injury in rats and the protective role of thiol-reductants. Renal failure 2015;In Press;1-5.
  66. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Analyt Biochem 1978;86;271-278.
  67. Jamshidzadeh A, Heidari R, Razmjou M, Karimi F, Moein MR, Farshad O, Akbarizadeh AR, Shayesteh MRH. An in vivo and in vitro investigation on hepatoprotective effects of Pimpinella anisum seed essential oil and extracts against carbon tetrachloride-induced toxicity. Iran J Bas Med Sci 2015;18;205-211.
  68. Alia M, Horcajo C, Bravo L, Goya L. Effect of grape antioxidant dietary fiber on the total antioxidant capacity and the activity of liver antioxidant enzymes in rats. Nut Res 2003;23;1251-1267.
  69. Jamshidzadeh A, Heidari R, Mohammadi-Samani S, Azarpira N, Najbi A, Jahani P, Abdoli N. A Comparison between the Nephrotoxic Profile of Gentamicin and Gentamicin Nanoparticles in Mice. J Biochem Mol Toxicol 2015;29;57-62.
  70. Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. Microbiol Lett 2003;226;195-202.
  71. Fang Y-J, Chiu C-H, Chang Y-Y, Chou C-H, Lin H-W, Chen M-F, Chen Y-C. Taurine ameliorates alcoholic steatohepatitis via enhancing self-antioxidant capacity and alcohol metabolism. Food Res Int 2011;44;3105-3110.
  72. Heidari R, Babaei H, Eghbal MA. Amodiaquine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine. Research in Pharmaceutical Sciences 2014;9;97-105.
  73. Miyazaki T, Matsuzaki Y. Taurine and liver diseases: a focus on the heterogeneous protective properties of taurine. Amino Acids 2012;46;101-110.
  74. Parvez S, Tabassum H, Banerjee BD, Raisuddin S. Taurine Prevents Tamoxifen-Induced Mitochondrial Oxidative Damage in Mice. Bas Clin Pharmacol Toxicol 2008;102;382-387.
  75. Alhumaidha KA, Saleh DO, Abd El Fattah MA, El-Eraky WI, Moawad H. Cardiorenal protective effect of taurine against cyclophosphamide-induced toxicity in albino rats. Can J Physiol Pharmacol 2015;In Press;1-9.
  76. Oja SS, Saransaari P. Pharmacology of taurine. 2007.
  77. Timbrell JA, Seabra V, Waterfield CJ. The in vivo and in vitro protective properties of taurine. General Pharmacology: The Vascular System 1995;26;453-462.
  78. Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clinical Cancer Research 1999;5;2192-2197.
  79. DeLeve LD. Dacarbazine toxicity in murine liver cells: a model of hepatic endothelial injury and glutathione defense. Journal of Pharmacology and Experimental Therapeutics 1994;268;1261-1270.
  80. Tripathi DN, Jena GB. Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: role of Nrf2, p53, p38 and phase-II enzymes. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2010;696;69-80.
  81. Lu Y, Cederbaum AI. Cisplatin-Induced Hepatotoxicity Is Enhanced by Elevated Expression of Cytochrome P450 2E1. Toxicological Sciences 2006;89;515-523.
  82. Duthie SJ, Grant MH. The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells. Brit J Cancer 1989;60;566.
  83. Gürer H, Ozgünes H, Saygin E, Ercal N. Antioxidant effect of taurine against lead-induced oxidative stress. Arch Envir Cont Toxicol 2001;41;397-402.
  84. Nandhini ATA, Thirunavukkarasu V, Ravichandran MK, Anuradha CV. Effect of taurine on biomarkers of oxidative stress in tissues of fructose-fed insulin-resistant rats. Sing Med J 2005;46;82-87.
  85. Parildar-Karpuzoğlu H, Mehmetçik G, Ozdemirler-Erata G, Doğru-Abbasoğlu S, Koçak-Toker N, Uysal M. Effect of taurine treatment on pro-oxidant-antioxidant balance in livers and brains of old rats. Pharmacol Rep 2008;60;673-678.
  86. Schaffer SW, Azuma J, Mozaffari M. Role of antioxidant activity of taurine in diabetes. Canad J Physiol Pharmacol 2009;87;91-99.
  87. Schaffer S, Azuma J, Takahashi K, Mozaffari M, Why is taurine cytoprotective?, in Taurine 52003, Springer. p. 307-321.
  88. Zhong Z, Jones S, Thurman RG. Glycine minimizes reperfusion injury in a low-flow, reflow liver perfusion model in the rat. American Journal of Physiology-Gastrointestinal and Liver Physiology 1996;270;G332-G338.
  89. Yin M, Ikejima K, Arteel GE, Seabra V, Bradford BU, Kono H, Rusyn I, Thurman RG. Glycine accelerates recovery from alcohol-induced liver injury. J Pharmacol Exp Therap 1998;286;1014-1019.
  90. Xu FL, You HB, Li XH, Chen XF, Liu ZJ, Gong JP. Glycine attenuates endotoxin-induced liver injury by downregulating TLR4 signaling in Kupffer cells. Amr J Surgery 2008;196;139-148.
  91. Mikalauskas S, Mikalauskiene L, Bruns H, Nickkholgh A, Hoffmann K, Longerich T, Strupas K, Büchler MW, Schemmer P. Dietary glycine protects from chemotherapy-induced hepatotoxicity. Amino Acids 2010;40;1139-1150.
  92. Kim T, Kim AK, Taurine Enhances Anticancer Activity of Cisplatin in Human Cervical Cancer Cells, in Taurine 8, A.E. Idrissi and W.J. L'Amoreaux, Editors. 2013, Springer New York. p. 189-198.
  93. Desai TK, Maliakkal J, Kinzie JL, Ehrinpreis MN, Luk GD, Cejka J. Taurine deficiency after intensive chemotherapy and/or radiation. Amr J Clin Nut 1992;55;708-711.
  94. Savarese DMF, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003;29;501-513.